• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

英国4个中心在B.1.1.529奥密克戎毒株流行高峰期新冠药物配送单位初始阶段的人口统计学特征及结果:一项服务评估

Demographics and Outcomes of Initial Phase of COVID-19 Medicines Delivery Units Across 4 UK Centers During Peak B1.1.529 Omicron Epidemic: A Service Evaluation.

作者信息

Brown Michael, Saund Jasjot, Qureshi Azka, Plowright Megan, Drury Katie, Gahir Joshua, Simpson Tom, Newman Thomas, Adams Kate, Galloway James, Durairaj Kezia, Elgizouli Kamla, Rampling Tommy, Cole Joby, Easom Nicholas, Goodman Anna L, Marks Michael

机构信息

Division of Infection, University College London Hospitals NHS Foundation Trust, London, United Kingdom.

Clinical Research Department, London School of Hygiene and Tropical Medicine, London, United Kingdom.

出版信息

Open Forum Infect Dis. 2022 Oct 6;9(10):ofac527. doi: 10.1093/ofid/ofac527. eCollection 2022 Oct.

DOI:10.1093/ofid/ofac527
PMID:36320201
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9605703/
Abstract

BACKGROUND

COVID-19 medicines delivery units (CMDU) were established in late December 2021 to deliver early antiviral therapy to patients classified as at risk with the aim of preventing hospitalization.

METHODS

We performed a service evaluation at 4 CMDUs in England. We assessed demographics and triage outcomes of CMDU referral, uptake of antiviral therapy, and the rate of subsequent hospitalizations within 2 weeks of CMDU referral.

RESULTS

Over a 3-week period, 4788 patients were referred and 3989 were ultimately assessed by a CMDU. Overall, 832 of the patients referred (17%) were judged eligible for treatment and 628 (13%) were ultimately prescribed an antiviral agent. The overall rate of admission within 14 days was 1%. Patients who were admitted were significantly older than those who did not require hospitalization. Of patients prescribed molnupiravir and sotrovimab, 1.8% and 3.2%, respectively, were admitted.

CONCLUSIONS

There was a high volume of referrals to CMDU service during the initial surge of the Omicron wave in the United Kingdom. A minority of patients were judged to be eligible for therapy. In a highly vaccinated population, the overall hospitalization rate was low.

摘要

背景

2021年12月下旬设立了新冠病毒-19药物配送单位(CMDU),为被归类为高危的患者提供早期抗病毒治疗,以防止住院。

方法

我们在英国的4个CMDU进行了服务评估。我们评估了CMDU转诊的人口统计学和分诊结果、抗病毒治疗的接受情况以及CMDU转诊后2周内的后续住院率。

结果

在3周的时间里,有4788名患者被转诊,最终有3989名患者由CMDU进行了评估。总体而言,被转诊的患者中有832名(17%)被判定符合治疗条件,628名(13%)最终被开具了抗病毒药物。14天内的总体住院率为1%。入院的患者明显比那些不需要住院的患者年龄大。在开具莫努匹韦和索托维单抗的患者中,分别有1.8%和3.2%的患者入院。

结论

在英国奥密克戎毒株浪潮初期,CMDU服务的转诊量很大。少数患者被判定符合治疗条件。在疫苗接种率很高的人群中,总体住院率较低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e250/9605703/d3e62d41a3af/ofac527f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e250/9605703/545ccd7ed31b/ofac527f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e250/9605703/d3e62d41a3af/ofac527f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e250/9605703/545ccd7ed31b/ofac527f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e250/9605703/d3e62d41a3af/ofac527f2.jpg

相似文献

1
Demographics and Outcomes of Initial Phase of COVID-19 Medicines Delivery Units Across 4 UK Centers During Peak B1.1.529 Omicron Epidemic: A Service Evaluation.英国4个中心在B.1.1.529奥密克戎毒株流行高峰期新冠药物配送单位初始阶段的人口统计学特征及结果:一项服务评估
Open Forum Infect Dis. 2022 Oct 6;9(10):ofac527. doi: 10.1093/ofid/ofac527. eCollection 2022 Oct.
2
Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform.在社区患者中比较 sotrovimab 和 molnupiravir 预防重症 COVID-19 结局的效果:利用 OpenSAFELY 平台开展的观察性队列研究。
BMJ. 2022 Nov 16;379:e071932. doi: 10.1136/bmj-2022-071932.
3
Evaluation of outpatient treatment for non-hospitalised patients with COVID-19: The experience of a regional centre in the UK.评估英国区域中心非住院 COVID-19 患者的门诊治疗:经验分享。
PLoS One. 2023 Mar 15;18(3):e0281915. doi: 10.1371/journal.pone.0281915. eCollection 2023.
4
Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study.在威尔士,使用莫努匹拉韦、奈玛特韦-利托那韦和索特罗维单抗预防 COVID-19 高风险患者住院的真实世界效果:一项回顾性队列研究。
J Infect. 2023 Apr;86(4):352-360. doi: 10.1016/j.jinf.2023.02.012. Epub 2023 Feb 10.
5
Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life.莫努匹韦、奈玛特韦/利托那韦或索托维单抗用于感染奥密克戎变异株的高危COVID-19患者:现实生活中的住院率、死亡率及核酸检测转阴时间
Pharmaceuticals (Basel). 2023 May 9;16(5):721. doi: 10.3390/ph16050721.
6
Efficacy and Safety of Sotrovimab Versus Oral Antiviral for Early Treatment in High-Risk Patients in Omicron Era: A Multicenter Retrospective Study.索托维单抗与口服抗病毒药物在奥密克戎时代高危患者早期治疗中的疗效和安全性:一项多中心回顾性研究
Pathogens. 2025 Feb 22;14(3):216. doi: 10.3390/pathogens14030216.
7
Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk patients during Omicron waves: observational cohort study using the OpenSAFELY platform.在奥密克戎毒株流行期间,使用OpenSAFELY平台进行的观察性队列研究:评估奈玛特韦/利托那韦与索托维单抗和莫努匹韦相比,在预防非住院高危患者出现严重新冠病毒病结局方面的有效性。
Lancet Reg Health Eur. 2023 Oct 8;34:100741. doi: 10.1016/j.lanepe.2023.100741. eCollection 2023 Nov.
8
Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England: a retrospective cohort study.在英国,高疾病进展风险的 COVID-19 患者接受 sotrovimab、口服抗病毒药物或无治疗的特征和结局:一项回顾性队列研究。
Curr Med Res Opin. 2024 Aug;40(8):1323-1334. doi: 10.1080/03007995.2024.2376144. Epub 2024 Jul 8.
9
Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment: a retrospective cohort study.接受 sotrovimab、口服抗病毒药物或未接受治疗的 COVID-19 高疾病进展风险患者的特征和结局:一项回顾性队列研究。
BMC Infect Dis. 2024 Jul 4;24(1):670. doi: 10.1186/s12879-024-09576-7.
10
Comparative effectiveness of sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in patients on kidney replacement therapy: observational study using the OpenSAFELY-UKRR and SRR databases.索托维单抗和莫努匹拉韦在预防接受肾脏替代治疗的患者出现严重 COVID-19 结局方面的比较有效性:使用 OpenSAFELY-UKRR 和 SRR 数据库的观察性研究
Clin Kidney J. 2023 Aug 29;16(11):2048-2058. doi: 10.1093/ckj/sfad184. eCollection 2023 Nov.

引用本文的文献

1
Comparative Effectiveness of Antivirals and Monoclonal Antibodies for Treating COVID-19 Patients Infected With Omicron Variant: A Systematic Review and Network Meta-Analysis.抗病毒药物和单克隆抗体治疗感染奥密克戎变异株的COVID-19患者的比较疗效:一项系统评价和网状Meta分析
Influenza Other Respir Viruses. 2024 Dec;18(12):e70065. doi: 10.1111/irv.70065.
2
Predictive Value of Blood Urea Nitrogen/Albumin Ratio in Mortality in Moderate to Severe COVID-19 Patients: A Retrospective Observational Analysis.血尿素氮/白蛋白比值对中重度新型冠状病毒肺炎患者死亡率的预测价值:一项回顾性观察分析
Cureus. 2023 Nov 6;15(11):e48416. doi: 10.7759/cureus.48416. eCollection 2023 Nov.
3

本文引用的文献

1
Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study.奥密克戎和德尔塔变异株主导期间感染新型冠状病毒(SARS-CoV-2)个体的症状流行率、持续时间及住院风险:来自ZOE COVID研究的一项前瞻性观察性研究
Lancet. 2022 Apr 23;399(10335):1618-1624. doi: 10.1016/S0140-6736(22)00327-0. Epub 2022 Apr 7.
2
Age-specific rate of severe and critical SARS-CoV-2 infections estimated with multi-country seroprevalence studies.用多国血清流行率研究估计特定年龄组严重和危重症 SARS-CoV-2 感染的发生率。
BMC Infect Dis. 2022 Mar 29;22(1):311. doi: 10.1186/s12879-022-07262-0.
3
Neutralizing Monoclonal Antibody Use and COVID-19 Infection Outcomes.
中和单克隆抗体的使用与 COVID-19 感染结局。
JAMA Netw Open. 2023 Apr 3;6(4):e239694. doi: 10.1001/jamanetworkopen.2023.9694.
4
Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY.社区环境中新冠病毒病抗病毒药物和中和单克隆抗体接受者的趋势、变异及临床特征:OpenSAFELY中2340万人的回顾性描述性队列研究
BMJ Med. 2023 Jan 13;2(1):e000276. doi: 10.1136/bmjmed-2022-000276. eCollection 2023.
5
Impact of vaccination on hospitalization and mortality from COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience.疫苗接种对原发性和继发性免疫缺陷患者因 COVID-19 住院和死亡的影响:英国的经验。
Front Immunol. 2022 Sep 23;13:984376. doi: 10.3389/fimmu.2022.984376. eCollection 2022.
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.
比较分析英国住院和死亡风险与 SARS-CoV-2 奥密克戎(B.1.1.529)和德尔塔(B.1.617.2)变异株的关系:一项队列研究。
Lancet. 2022 Apr 2;399(10332):1303-1312. doi: 10.1016/S0140-6736(22)00462-7. Epub 2022 Mar 16.
4
Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients.血液透析患者新冠病毒疫苗接种后的奥密克戎中和抗体
Lancet. 2022 Feb 26;399(10327):800-802. doi: 10.1016/S0140-6736(22)00104-0. Epub 2022 Jan 20.
5
Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination.接种同源或异源科兴疫苗或辉瑞疫苗后针对奥密克戎变异株 BA.1 的中和抗体。
Nat Med. 2022 Mar;28(3):486-489. doi: 10.1038/s41591-022-01704-7. Epub 2022 Jan 20.
6
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.奥密克戎对抗体中和作用的逃逸显著。
Nature. 2022 Feb;602(7898):671-675. doi: 10.1038/s41586-021-04389-z. Epub 2021 Dec 23.
7
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.瑞德西韦早期治疗可降低门诊患者重症 COVID-19 进展风险
N Engl J Med. 2022 Jan 27;386(4):305-315. doi: 10.1056/NEJMoa2116846. Epub 2021 Dec 22.
8
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.莫努匹韦片用于非住院 COVID-19 患者的口服治疗。
N Engl J Med. 2022 Feb 10;386(6):509-520. doi: 10.1056/NEJMoa2116044. Epub 2021 Dec 16.
9
Trends and clinical characteristics of COVID-19 vaccine recipients: a federated analysis of 57.9 million patients’ primary care records in situ using OpenSAFELY.利用 OpenSAFELY 在原地对 5790 万患者的初级保健记录进行的联邦分析显示,COVID-19 疫苗接种者的趋势和临床特征。
Br J Gen Pract. 2021 Dec 31;72(714):e51-e62. doi: 10.3399/BJGP.2021.0376. Print 2022 Jan.
10
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.Sotrovimab 对 SARS-CoV-2 中和抗体用于治疗新型冠状病毒早期感染。
N Engl J Med. 2021 Nov 18;385(21):1941-1950. doi: 10.1056/NEJMoa2107934. Epub 2021 Oct 27.